Chronic graft-versus-host disease (cGVHD) is a multiorgan disorder with skin manifestations resembling scleroderma. Since photopheresis, a treatment that induces an anticlonotypic immune response, has proven to be effective in both cutaneous T cell lymphomas with circulating clonal T cells and in cGVHD, we have searched for circulating clonal T cell populations in patients with cGVHD, and determined whether T cell clonality in the blood is associated with therapeutic response. We screened blood samples from 27 patients after HLA-matched allogeneic bone marrow transplantation (allo-BMT), 10 without cGVHD and 17 with extensive cGVHD, for clonal T cell receptor ␥ (TCR␥) gene rearrangements using fluorescent-based polymerase chain reaction (PCR) and automated high-resolution capillary electrophoresis. Amplified populations of clonal T cells with unique TCR␥ gene rearrangements were found in six of 10 (60%) allo-BMT patients without cGVHD and 13 of 17 (76.5%) allo-BMT patients with cGVHD (P = 0.41), as compared to none of 10 (0%) healthy controls. Twelve patients with cGVHD were treated by photopheresis, and the presence of amplified populations of clonal T cells was found to be associated with a cutaneous response to photopheresis, as eight of eight (100%) clone-positive vs none of four (0%) clonenegative patients experienced a clinically significant cutaneous response to treatment (P = 0.001). Our findings suggest that patients with cGVHD that have detectable expanded clonal T cell populations in their peripheral blood, may be more likely to respond to treatment by photopheresis. Bone marrow transplantation for leukemia results in longterm survival in approximately 50% of patients.
Bone marrow transplantation for leukemia results in longterm survival in approximately 50% of patients. 1 These long-term survivors, otherwise cured of their disease, are at risk of complications that include chronic graft-versushost disease (cGVHD). The pathogenesis of cGVHD is complex and involves an immune-mediated attack by transplanted donor lymphocytes and autoreactive phenomena due to the activation of immunologic pathways that bear similarities to those involved in several autoimmune disorders. [1] [2] [3] Despite conventional and new therapies for the prevention or treatment of chronic GVHD (cGVHD), this syndrome continues to account for significant morbidity and is lethal in 20% to 40% of affected patients. 4, 5 Photopheresis, a leukapheresis-based therapy that combines 8-methoxypsoralen and ultraviolet A irradiation, has recently been shown to be an effective treatment for advanced cutaneous T cell lymphoma (CTCL), but has also shown efficacy in cGVHD. [6] [7] [8] In CTCL, clinical responsiveness to photopheresis has been shown to be dependent on the presence of detectable circulating clonal T cells in the peripheral blood. 6 Given the responsiveness of certain, but not all, cases of cGVHD to photopheresis, we investigated whether circulating clonal T cell populations are detectable in cGVHD patients, and if their presence could predict clinical response to photopheresis, as is the case in CTCL.
Methods

Patients and therapy
Ten HLA-matched allogeneic bone marrow transplanted (BMT) patients without signs of cGVHD and 17 with extensive cGVHD for whom blood sampling had been performed at least 100 days after BMT or at the onset of cGVHD were selected for analysis of clonal T cell receptor ␥ (TCR␥) rearrangement performed as described below. Twelve of the patients having cGVHD with generalized cutaneous involvement received or had received photopher-esis treatment. Diagnosis of cGVHD and its classification into clinical limited or clinical extensive disease was based on clinical, laboratory, and histologic data and performed according to published criteria. 3, 9 Chronic GVHD was defined as persistent skin lesions, mouth ulcers, and/or diarrhea, and/or liver function abnormalities, and/or lung function abnormalities that presented at least 100 days after BMT, and persisted for at least 4 weeks in the absence of any other cause. In all cases, the pathological process was confirmed histologically. Chronic GVHD had a progressive onset if it followed as a direct extension of acute GVHD.
Photopheresis was performed on 2 consecutive days, once monthly, using a photopheresis system (UVAR, Therakos, West Chester, PA, USA) as described. 7 Briefly, 2 h after the ingestion of 0.6 mg of 8-methoxypsoralen per kilogram body weight, patients underwent a discontinuous leukapheresis procedure with exposure of removed leukocytes to ultraviolet A radiation within the UVAR device. During the procedure, approximately 240 ml of leukocyteenriched blood is mixed with 300 ml of the patient's plasma and 200 ml of sterile normal saline plus approximately 10 000 U of heparin. The final buffy coat preparation contains an estimated 25-50% of the total peripheral blood mononuclear cell (PBMC) compartment and a hematocrit content of 2.5-7%. The buffy coat is then passed as a 1 mm film through a sterile cassette, permitting a 180-min exposure to ultraviolet A light, yielding an average exposure per lymphocyte of 2 J/cm 2 . Following this procedure, the buffy coat is returned to the patient.
Clinical assessment of patients was performed at baseline (before photopheresis) and regularly thereafter by one single physician without knowledge of the results of the molecular analysis of T cell clonality. Briefly, the following parameters were recorded at baseline: (1) the severity of skin involvement (sclerodermatous) in % of body surface area (0-25, 26-50, 51-75, 76-100); (2) the presence or absence of erosions and/or ulcers in the buccal mucosa; and (3) the reduction in the amplitude of articular motion (0-25, 26-50, 51-75, 76-100). Liver function tests were followed in patients in which they were elevated at onset of photopheresis (baseline). A complete response (CR) of chronic GVHD was defined as complete resolution of skin, joint, oral mucosa, or liver manifestations. A partial response was defined as a greater than 50% (but less than complete) improvement of skin, joint, oral mucosa, or liver manifestations. No change (NC) was defined as stable disease despite photopheresis.
Molecular analysis
Blood was obtained from patients prior to the onset of photopheresis treatment, and PBMC were immediately isolated from whole blood using the Ficoll-Hypaque technique. Samples were then frozen in liquid nitrogen until analysis for clonal T cell receptor ␥ (TCR␥) rearrangements using polymerase chain reaction (PCR) and automated high-resolution capillary electrophoresis. Briefly, DNA was prepared from PBMC, and PCR used to amplify a specific region of the TCR␥ gene by using two primer mixes to cover all possible V␥ and J␥ combinations. 10 The first mix contains consensus primers V␥ 1-8 and three fluoresceinated J␥ primers, and the second mix contains primers V␥ 9-12 and the three fluoresceinated J␥ primers. The PCR products are then denatured and fluorescent fragments are size separated using capillary electrophoresis (ABI PRISM 310 Genetic Analyzer). Size determination (Ϯ1 bp) and product quantitation were accomplished using ABI GeneScan 3.1 software (PE Applied Biosystems, Foster City, CA, USA). From the electrophoretic profiles, predominant clones in a background polyclonal population were identified by calculating the ratio of peak heights between a peak of concern and the average of two immediate flanking peaks (Rn value). An Rn of Ͼ3.0 was considered to be diagnostic of a monoclonal population based on analysis of 21 cases of T cell lymphoma and 10 benign control specimens. 11 Using this technique, the sensitivity of detecting a monoclonal population of T cells within a polyclonal background in blood is between 1 and 5% depending on the percent nonclonal background T cells in a specimen.
Results
T cell clonality in patients with cGVHD
Analysis of T cell clonality using high-resolution fluorescent TCR␥ PCR analysis of peripheral blood mononuclear cells (PBMC) was performed in 17 patients with cGVHD (mean time from BMT to TCR clonality analysis: 340 Ϯ 87 days), 10 BMT patients without signs of cGVHD (mean time from BMT to TCR clonality analysis: 595 Ϯ 373 days) and 10 healthy controls. High-resolution fluorescent TCR␥ PCR analysis of PBMC revealed the presence of circulating amplified populations of clonal T cells with unique TCR␥ gene rearrangements in none of 10 healthy controls, six of 10 (60%) BMT patients without cGVHD, and 13 of 17 (76.5%) BMT patients with cGVHD (P = 0.41, Fisher's exact test).
Clinical characteristics and T cell clonality of cGVHD patients treated by photopheresis
Twelve of the above patients with cGVHD were treated by photopheresis at a time when their T cell clonality status was unknown. The clinical characteristics of these 12 patients are summarized in Table 1 . All patients had progressive sclerodermatous skin changes, and some patients had involvement of other organs (Table 2) . Eight patients (67%) had amplified populations of clonal T cells with unique TCR␥ gene rearrangements in their peripheral blood (clone-positive), whereas four did not (clone-negative) ( Table 1 and Figure 1 ). The age of the eight cGVHD patients with amplified circulating populations of clonal T cells was slightly but not significantly (P = 0.12) lower (mean 38.3 years, s.d. 8.7) than the four patients without circulating clonal T cells (mean 47.8 years, s.d. 9.9) ( Table  1 ). The mean age of the 10 patients in our control group, all of whom were clone negative was 37.7 years (s.d. 6.5). The baseline skin involvement (% of body surface involved) was similar or more severe in the clone-positive group of patients (Table 1) . CML = chronic myeloid leukemia; NHL = non-Hodgkin's lymphoma; CLL = chronic lymphocytic leukemia; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; MM = myeloid metaplasia; SMM = single mismatch; CY = cyclophosphamide; VP16 = etoposide; fTBI = fractionated total body irradation; CsA = cyclosporine; MTX = methotrexate; FLU = fludarabine; CYT = cytoxan; BU = busulfan; PRE = prednisone.
T cell clonality and responsiveness to photopheresis
Analysis of clinical parameters in the 12 patients who were treated by photopheresis revealed that the interval between BMT and the onset of cGVHD was on average slightly but not significantly (P = 0.59) longer in the clone-positive group of patients (300 days, s.d. 176 days) than in the clone-negative group (243 days, s.d. 143 days) ( Table 2 ). The total number of photopheresis cycles was lower in the clone-negative (non-responder) patients as photopheresis was discontinued in the absence of an objective response after five to six consecutive cycles. It is our experience that responders present an objective response already within the first four cycles of photopheresis. Otherwise, the time from BMT to onset of photopheresis and the time between BMT and analysis of T cell clonality were similar in the group of patients with and without a T cell clone (Table 2 and not shown). Analysis of clinical response to photopheresis, although limited by the small number of patients, showed that photopheresis appears to be of greater therapeutic benefit to clone-positive as opposed to clone-negative cGVHD patients (Table 2 ). This distinct therapeutic effect was most evident in the skin, but also translated itself by a decrease in immunosuppressive treatment for several patients (Table  2) . In all eight clone-positive cGVHD patients a significant improvement in skin manifestations was observed (six PR and two CR), whereas no improvement was observed in the four clone-negative patients (P = 0.001, Fisher's exact test). Likewise, in six of eight (75%) clone-positive patients but only one of the clone-negative patients (25%), daily oral doses of prednisone were reduced. It should be noted however that one (patient 7) of the eight clone-positive patients in whom prednisone was reduced was started on cyclosporin and mycophenolate, and that there was an improvement (partial response) in the non-cutaneous manifestations in two of four clone-negative cGVHD patients.
Analysis of T cell clonality after completion of photopheresis and occurrence of a clinical response did not reveal any modifications in the T cell receptor profile (not shown), suggesting that response to photopheresis does not correlate Bone Marrow Transplantation with disappearance of the clonally amplified T cell populations.
Discussion
The results described here reveal a high frequency of clonal amplification of T cells in allo-BMT patients analyzed at more than 100 days after BMT, with a slight but non-significant predominance in the group of patients suffering from cGVHD. Most interestingly, however, they provide evidence suggesting a correlation between the presence of an expanded monoclonal T cell population in the circulation of patients with cGVHD and cutaneous response to photopheresis.
Clonal amplification of T cells is a feature that is characteristically observed in malignancies involving the T cell lineage such as cutaneous T cell lymphomas, T cell leukemias and certain non-Hodgkin's lymphomas. It has recently become apparent, however, that it can also be detected in non-malignant conditions including certain autoimmune and infectious diseases, [12] [13] [14] [15] and even occasionally although rarely in apparently healthy humans. 16, 17 The technique we used here for the detection of TCR␥ gene rearrangements did not reveal the presence of circulating clonal T cells in any of the healthy controls tested. Likewise, none of the patients with clonal T cell expansions in this study had clinical or laboratory parameters suggestive of T cell lymphoma or leukemia relapse at the time of analysis or followup (Ͼ3 months). The amplification of clonal T cell populations observed in our patients is therefore most probably related to their medical conditions, bone marrow transplantation and/or cGVHD.
The precise cause of the clonal T cell expansions observed in our patients is at present unclear, but may be related to two distinct processes. First, studies analyzing T cell repopulation after allo-BMT have clearly shown that expansion of the T cell compartment restores T cell numbers but without reconstituting the diversity of the T cell repertoire.
18-21 Studies comparing T cell depleted and Table 2 Response to photopheresis in clone-positive and clone-negative patients with cGVHD 216 218 220 222 224 226 228 230 232 234 236 238 240 242 244 246 248 250   3000  2000  1000   165  170  175  180  185  190  195  200   1500  1000   500   150  155  160  165  170  175  180  185  190  195  200   900  600   300   150  155  160  165  170  175  180  185  190  195 unmanipulated grafts further suggest that this is due, during the first year after transplantation, to rapid expansion of restricted populations of transfused donor and surviving host T cells. 20 At later times, repopulation of the peripheral T cell pool by thymic production leads to a wider T cell repertoire. 21 However, thymic dysfunction is known to be enhanced by GVHD, and this could potentially result in an increased incidence of clonal T cell amplifications in patients with GVHD as compared to those without GVHD. In accordance with this, Verfeurth et al 22 have recently shown by third complementarity region (CDR3) spectratyping of 19 BMT patients of whom four developed GVHD after donor lymphocyte infusion, that irregularities in the spectratypes were more important after the onset of GVHD. It is, in our opinion, unlikely that the differences in incidence of clonal T cell amplifications observed in our patients with GVHD as compared to those without GVHD are uniquely due to the time at which TCR␥ gene rearrangement analysis was performed, as the mean time between BMT and analysis was if anything longer in the cGVHD group of patients.
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Second, the clonal expansions observed here may be antigen-driven and related to other factors that also play a role in regulating the profile of the T cell repertoire. Such factors include infections that are frequent after BMT, and infectious microorganisms are known to be able to induce strong cellular immune responses. They also include GVHD itself, and activation of T cells by alloantigens. In acute GVHD, Dietrich et al 23 have shown in vivo T cell clonal amplification preferentially or exclusively observed in the skin, a major target tissue of GVHD, providing evidence in favor of GVHD-related antigen driven T cell clonal expansion. A similar mechanism may account in part for the increased frequency of clonal T cell amplification observed in our patients with cGVHD as compared to those without GVHD.
Photopheresis is an effective treatment for cGVHD. In a recent study photopheresis was shown to induce complete responses of cutaneous cGVHD in 12 of 15 (80%) patients. In our study we observed a similar response rate for cutaneous cGVHD (eight of 12 (67%) response), but a lower incidence of complete responses (two complete responses and six partial responses). The mechanism by which photophoresis is of therapeutic benefit in cGVHD is at present unclear. Photopheresis and its mechanism of action have been best studied in patients with Sezary syndrome, the leukemic form of cutaneous T cell lymphoma (CTCL). 6, 24 In this disease, photopheresis induces longterm clinical responses and possibly enhanced survival rates. [25] [26] [27] [28] Accumulating evidence suggests that the therapeutic effect of photopheresis in CTCL is dependent on the presence of circulating clonally amplified T cells, and due to the induction of an immune response against defined lymphocyte populations that are central to its pathogenesis (for review see Ref. 6) . Experimental data acquired from animal autoimmune and transplantation studies suggest that photopheresed cells induce an antigen-specific immune response directed to pathogenic T cell populations without affecting general immunocompetence. [29] [30] [31] In our patients, however, no decrease or disappearance of the clonal population of T cells was observed after photopheresis. The mechanism by which photopheresis brings about clinical improvement in this situation therefore remains unclear, but could potentially involve modulation of T cell function.
In the case of cGVHD, there is strong evidence of ongoing abnormal immune activation detectable by the presence of activated T cells both within the peripheral blood and lesional skin (for review see Refs 32 and 33). These cells directly and/or indirectly mediate tissue damage in cGVHD. Our data now provide evidence that a high proportion of patients with cGVHD have detectable expanded clonal T cell populations in their peripheral blood. The clinical data reported herein, although preliminary, suggest that the cutaneous manifestations in cGVHD patients with circulating clonal T cells have a greater chance of responding to photopheresis. They also support the previously described reports that photopheresis may be most effective in diseases with circulating clonally amplified T cells. Futhermore, if these results are confirmed in larger series of patients, TCR␥ gene rerrangement analysis may prove of use in predicting potential responders to photopheresis before the onset of treatment.
